Table 1.
Patient and disease characteristics
| Characteristics | No. of patients = 111 |
|---|---|
| Median age, y (range) | 54 (21-67) |
| Follow-up | |
| Median follow-up days for all 111 patients (range) | 665 (32-2408) |
| Median follow-up days for 67 patients alive at last follow-up (range) | 882 (379-2408) |
| Diagnosis, no. (%) | |
| Lymphoid | 64 (57.7) |
| Non-Hodgkin lymphoma | 57 (89.1%) |
| De novo diffuse large B-cell NHL | 14 (21.9) |
| Diffuse large B-cell NHL with evidence of transformation from follicular NHL | 9 (14.1) |
| Mantle-cell lymphoma | 13 (20.3) |
| Follicular small-cleaved NHL | 10 (15.6) |
| Small lymphocytic leukemia/chronic lymphocytic leukemia or prolymphocytic leukemia | 7 (10.9) |
| Angioimmunoblastic lymphoma | 2 (3.1) |
| Peripheral T-cell lymphoma | 1 (1.6) |
| NKT-cell lymphoma | 1 (1.6) |
| Hodgkin lymphoma | 5 (7.8) |
| Pre-B acute lymphoblastic leukemia | 2 (3.1) |
| Advanced-stage disease* | 55 (85.9) |
| Prior autologous transplantation | 32 (50.0) |
| Myeloid | 47 (42.3) |
| De novo AML | 38 (80.9) |
| Favorable cytogenetic risk | |
| t(8:21), inv(16), or t(16:16) | 2 (5.3) |
| t(15:17) APL | 2 (5.3) |
| Intermediate cytogenetic risk | |
| Normal cytogenetics | 16 (42.1) |
| +8 | 1 (2.6) |
| Cytogenetics unknown | 11 (28.9) |
| Unfavorable cytogenetic risk | |
| del5q, t(6:9) −7, or complex | 6 (15.8) |
| AML evolved from MDS | 3 (6.4) |
| Myelodysplastic syndrome–RAEB | 2 (4.3) |
| Treatment-related AML | 1 (2.1) |
| Accelerated-phase CML | 3 (6.4) |
| Advanced-stage disease† | 30 (63.8) |
| Donor, no. (%) | |
| Related | 61 (54.9) |
| Fully matched | 60 (98.4) |
| 1-allele mismatched related donor | 1 (1.6) |
| Unrelated | 50 (45.0) |
| Fully matched | 45 (90.0) |
| 1-allele mismatched unrelated donor | 5 (10.0) |
| Sex mismatch, no. (%) | |
| M→M | 35 (31.5) |
| M→F | 24 (21.6) |
| F→M | 30 (27.0) |
| F→F | 22 (19.8) |
| Cytomegalovirus serologic status, no. (%) | |
| Donor, recipient, or both seropositive | 74 (66.7) |
| Donor and recipient seronegative | 24 (21.6) |
| Disease status at start of TLI and ATG, no. (%) | |
| Lymphoid | |
| Complete remission | 17 (26.6) |
| Partial remission | 38 (59.4) |
| Stable disease or progressive disease | 9 (14.1) |
| Myeloid | |
| 1st complete remission | 26 (55.3) |
| 2nd complete remission | 10 (21.3) |
| ≥ CR2, PR, SD, or PD | 11 (23.4) |
AML indicates acute myeloid leukemia; APL, acute promyelocytic leukemia; MDS, myelodysplastic syndrome; RAEB, refractory anemia with excess blasts; NHL, non-Hodgkin lymphoma; NOS, not otherwise specified; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; and MMF, mycophenolate mofetil.
Advanced-stage lymphoid malignant disease was defined as disease status beyond second complete remission or not in remission at the start of transplant conditioning.
Advanced-stage myeloid malignant disease was defined as a high-risk cytogenetic abnormality and age beyond 55 years at diagnosis, myelodysplastic syndrome with progression to acute myeloid leukemia AML, treatment-related AML, or disease.